Clicking on banner ads enables JWR to constantly improve
Jewish World Review Oct. 13, 2000 / 14 Tishrei 5760

James K. Glassman

Jim Glassman
JWR's Pundits
World Editorial
Cartoon Showcase

Mallard Fillmore

Michael Barone
Mona Charen
Linda Chavez
Greg Crosby
Larry Elder
Don Feder
Suzanne Fields
James Glassman
Paul Greenberg
Bob Greene
Betsy Hart
Nat Hentoff
David Horowitz
Marianne Jennings
Michael Kelly
Mort Kondracke
Ch. Krauthammer
Lawrence Kudlow
Dr. Laura
John Leo
David Limbaugh
Michelle Malkin
Jackie Mason
Chris Matthews
Michael Medved
MUGGER
Kathleen Parker
Wes Pruden
Debbie Schlussel
Sam Schulman
Amity Shlaes
Roger Simon
Tony Snow
Thomas Sowell
Cal Thomas
Jonathan S. Tobin
Ben Wattenberg
George Will
Bruce Williams
Walter Williams
Mort Zuckerman

Consumer Reports


Way to play biotech

http://www.jewishworldreview.com --
THERE'S NO doubt that biotechnology holds amazing promise in the fightagainst human suffering and disease. And the financial possibilities seem almost as promising. When you consider that all diseases have some genetic basis, it seems clear that big rewards await those companies that can use our new knowledge of the human genome to cure human illness.

The problem with biotechs has always been figuring out how to invest in this volatile sector. On the one hand, investing in a particular company with an exciting new therapy is extremely risky. Unless you have a Ph.D. in molecular biology, it's very difficult to assess the value of the firm's technology. And you can't judge the company on its financial performance, either, because biotechs typically lose millions for years while they're developing a drug, testing it, and then awaiting FDA approval. Unpredictable doesn't begin to cover it. You have to wait years before you even know whether they'll have a product on the market.

On the other hand, you could invest in large pharmaceutical firms that have licensed biotechnology or developed some of their own. But while this approach limits your downside - Merck is probably going to be in business next year - it obviously limits your upside, too. Even a fairly big hit in biotech could almost get lost in Merck's revenues.

The natural solution is to own a biotech fund. In the past I've recommended a variation on this theme - owning shares in Merrill Lynch's Biotech HOLDRs trust (Ticker symbol: BBH). HOLDRs are like mutual funds except the HOLDRs trade like stocks, the expenses are lower, and for a small fee the owner can take possession of the shares of the individual stocks in the trust. I still like BBH - by offering stakes in the largest, most profitable biotech firms, it provides a great way to invest in biotech for the long term.

But let's say that you really enjoy picking stocks and following specific companies. Or maybe you believe in the future of biotech, but you think that the current kings of the hill are overpriced and past their primes. Maybe you think that the greatest discoveries are likely to come from people and companies that we haven't even heard of yet. Well, another way to play the biotech age is to follow the strategy that has worked well for many investors in the Internet age. Don't buy stock in the gold miners - invest in the guys selling picks and shovels. Unsure about Amazon's business plan? Invest in Sun Microsystems or Microsoft, which make the hardware and software behind the dot-coms.

In a similar way, if you're not sure which company will cure cancer, invest in the people who provide equipment to those searching for cures. PE Biosystems Corp. (PEB) makes the gene sequencing machines that allow sister company PE Celera (CRA) to map the human genome. Waters Corporation (WAT) is a leader in liquid chromatography, which allows scientists to analyze the chemical content of a given substance - very useful in biotech labs.

You also might consider Agilent Technologies (A), which carries a very reasonable price/earnings ratio of 32. George Gilder likes Agilent for its innovations in fiber optics. You might like Agilent, the former testing and measurement division of Hewlett-Packard, for its medical lab equipment business. This company has solid revenue growth and may be ready for a rally after falling from a high of $162 per share all the way to a recent $49.

For more aggressive investors looking to accept a good deal of risk, there are three small, money-losing companies at the forefront of a very high-tech industry - making computer chips that analyze genetic material. All three have been punished of late by investors, but Affymetrix (AFFX), Caliper Technologies (CALP) and Nanogen (NGEN) seem to be in the right business at the right time.


JWR contributor James K. Glassman is the host of Tech Central Station. Comment by clicking here.

Up

10/12/00: Bush vs. Gore on Technology
10/11/00: Global Climate Scare: Fools Rush In
10/05/00: Avoid the Apple Trap
10/03/00: Goodbye, anti-Microsoft crusader --- and good riddance
09/29/00: Should You Invest in Tech IPOs?
09/27/00: Could technology end airline delays?
09/22/00: Donít Forget Small Caps
09/20/00: Is the New York Times Rooting for Disaster?
09/13/00: The Best Argument Against Net Regulation
08/30/00: Political Risk in Big Drug Stocks
07/27/00: Tech Dividends
07/25/00: Government Privacy Violators
07/20/00: If I Had to Pick One Tech Stock
07/18/00: Our Favorite Lawsuit
07/13/00: Silicon Valley East
07/11/00: Election 2000: Year of the Investor Class?
07/07/00: Adventures on the Amazon.com
07/06/00:The Difference Between Bill Gates and Larry Ellison
06/29/00: In the Chips
06/27/00: Free market wins in Federal Court!
06/22/00: Wireless Bargains?
06/20/00: Is Your SUV Warming the Planet?
06/15/00: Shopping for Government
06/13/00: Top 10 Tech Stocks
06/08/00: Riding the eBook Wave
06/06/00: "The Last Mile"
06/02/00: Keep Buying!
05/31/00: Who Asked the FTC to Regulate Online Privacy?
05/25/00: "When Itís Time to Sell"
05/23/00: End the "Telephone Tax"
05/16/00: Time Warner Gets a Bad Rap

© 2000, Tech Central Station